The Minds Behind Rewind

Jim Van heusden

Jim Van heusden

Executive Chairman, Managing Director bioskills bv

Jim Van heusden has served as member and executive chair of our board of directors since March 2018. Jim has more than 25 years’ experience in research and development and financial, business and operating management in the biotech industry. He is the managing director of bioskills bv. Previously, Jim served as chief executive officer of Karolinska Development, a publicly listed Nordic life science investment fund, where he executed a strategic turnaround and repositioned the company to become a leading Nordic life science investment company. Jim worked as a partner at Gimv, a Belgian based investment company, from 2001 – 2013 focusing on investments in life sciences.

Former investments and BoD representation include: Ablynx (acquired by Sanofi), ActoGeniX (acquired by Intrexon), Ambit Biosciences (acquired by Daiichi Sankyo), ChemoCentryx, CropDesign (acquired by BASF), Fovea Pharmaceuticals (acquired by Sanofi-Aventis), Hypnion (acquired by Eli Lilly), Movetis (acquired by Shire), Memory Pharmaceuticals (acquired by Hoffmann-La Roche), Multiplicom (acquired by Agilent Technologies), Nereus Pharmaceuticals (acquired by Triphase), Plexxikon (acquired by Daiichi Sankyo), Pronota (acquired by MyCartis), Prosensa (acquired by BioMarin), Santhera Pharmaceuticals, and Xanthus Pharmaceuticals (acquired by Antisoma).

Jim holds BSc and MSc degrees in chemistry and biochemistry from the University of Antwerp and a PhD in molecular and cellular biology from the University of Maastricht.

Guillaume Duvey portrait

Guillaume Duvey

Head of Medicinal Chemistry

Guillaume joined Rewind Therapeutics in February 2020 as Head of Medicinal Chemistry and brings over 20 years of experience in early and late-stage small molecule drug discovery in biotech/pharma.

Prior to joining Rewind, he co-founded in 2015 Pragma therapeutics, a biotech company focusing on the development of novel therapeutics for the treatment of stress-related and hearing disorders. As CSO he was in charge of the research and development of Pragma’s portfolio, leading to the nomination of a drug candidate for the treatment of PTSD.

From 2015 to 2018 he was Senior Director of Chemistry at Prexton therapeutics, where he led the CMC efforts for the development of Foliglurax, a novel mGlu4 positive allosteric modulator for the treatment of Parkinson’s disease, acquired by Lundbeck in 2018.

From 2004 to 2013 Guillaume served as Group Leader then as Research Director at Addex therapeutics where he led several preclinical programs, developing in particular novel allosteric modulators for glutamate receptors for various indications. His work led to numerous small molecule clinical candidate nominations for indications like Parkinson’s disease, anxiety, pain, gastroesophageal reflux disease and mood disorders. He notably led the research collaboration with Janssen Pharmaceutica in Belgium and Spain (J&J group), to develop novel mGlu2 allosteric modulators for the treatment of schizophrenia and anxious depression, and which delivered the clinical candidate ADX71149/JNJ40411813 still in clinical development.  During his tenure at Addex he was also responsible for developing strategical scientific partnerships and technological platform integrating modern techniques for identification, characterization and optimization of preclinical molecules for novel targets and new indications.

Prior to Addex, he joined in 2000 the R&D division of Janssen in France where he focused on small molecule drug discovery and advanced several research programs in oncology, virology and CNS disorders.

Guillaume holds a PhD in organic chemistry from University of Rouen (France) and is co-author of more than 25 patents and peer-reviewed articles, as well as a book chapter dedicated to drugs acting on mGlu2 and mGlu5.

Portrait of Christope Van Vaeck

Christophe Van Vaeck

Financial Consultant

Dr. Christophe Van Vaeck joined Rewind Therapeutics in October 2019 as part-time basis as Financial Advisor. He brings almost 20 years of operational and strategic experience from the Life Sciences financial community. Christophe is also CFO of Handl Therapeutics. Before that he managed for 10 years investments and successful exits for both early stage VC and mature PE companies in the biotech, diagnostic, medtech and healthcare service sectors at Gimv. Christophe held board positions at Multiplicom, Spinart, Almaviva Santé and others. During his time at KBC securities, he was actively involved in the successful initial public offerings and subsequent fundraisings of biotech companies such as Galapagos, Devgen, Thrombogenics and Ablynx. Christophe started his career at Bank Degroof in 2001, after obtaining a PhD in Molecular and Cellular Biology at KULeuven, Belgium. Since the end of 2017, Christophe has dedicated himself fully to organize promising Life Sciences companies to be ready for the next phase of their development.